SRR8752372
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.480
- PANCREAS_BETA_CELLS+0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.440
- P53_PATHWAY+0.420
- INTERFERON_ALPHA_RESPONSE+0.390
- INTERFERON_GAMMA_RESPONSE+0.360
- MTORC1_SIGNALING+0.340
- ANGIOGENESIS+0.330
- DNA_REPAIR+0.320
- MYC_TARGETS_V1+0.310
Top 10 suppressed
- MITOTIC_SPINDLE-0.530
- G2M_CHECKPOINT-0.500
- E2F_TARGETS-0.430
- TGF_BETA_SIGNALING-0.290
- NOTCH_SIGNALING-0.280
- UV_RESPONSE_DN-0.220
- SPERMATOGENESIS-0.200
- HEDGEHOG_SIGNALING-0.110
- APICAL_JUNCTION-0.090
- MYOGENESIS-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.806 |
| 2 | BS_R13X6TMW | pilocytic astrocytoma | — | 0.803 |
| 3 | SRR818348 | GTEX | — | 0.798 |
| 4 | SRR1078879 | GTEX | — | 0.785 |
| 5 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.773 |
| 6 | C884FB38-DE5C-48BA-95F1-4ABD2991E833 | — | — | 0.770 |
| 7 | BS_8Z3SCKB5 | subependymal giant cell astrocytoma(SEGA) | — | 0.769 |
| 8 | TCGA-49-4494-01A-01R-1206-07 | — | cohortA1 | 0.769 |
| 9 | TCGA-BA-5152-01A-02R-1873-07 | — | — | 0.761 |
| 10 | SRR1071880 | GTEX | — | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.470 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.440 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.420 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |